Trials / Completed
CompletedNCT00477672
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 298 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of two dose levels of pimavanserin (ACP-103) compared to placebo in patients with Parkinson's disease psychosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pimavanserin tartrate (ACP-103) | 10 mg, tablet, once daily by mouth, 6 weeks |
| DRUG | Pimavanserin tartrate (ACP-103) | 40 mg, tablet, once daily by mouth, 6 weeks |
| DRUG | Placebo | tablet, once daily by mouth, 6 weeks |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2009-06-01
- Completion
- 2009-07-01
- First posted
- 2007-05-24
- Last updated
- 2017-05-17
- Results posted
- 2014-03-26
Locations
78 sites across 7 countries: United States, Bulgaria, France, India, Russia, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00477672. Inclusion in this directory is not an endorsement.